The effect of ursodeoxycholic acid in cystic cholangiopathies

Autores: Lammert Frank, Méndez Sánchez Nahum


Article commented: D’Agnolo HM, Kievit W, Takkenberg RB, Riaño I, Bujanda L, Neijenhuis MK, Brunenberg EJ, et al. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol 2016; 65: 601-7. Comment: We have read with great interest the publication from Hedwig D’Agnolo, et al. on the effect of ursodeoxycholic acid (UDCA) in advanced polycystic liver disease due to autosomal-dominant polycystic kidney and/or liver diseases (ADPKD/ADPLD). The Dutch group of investigators reported interesting results on UDCA administration for 24 weeks. They reported a reduction of liver cyst volume growth but did not observe a reduction of total liver volume.

Palabras clave:

2016-11-18   |   261 visitas   |   Evalua este artículo 0 valoraciones

Vol. 15 Núm.6. Noviembre-Diciembre 2016 Pags. 949-950 Ann Hepatol 2016; 15(6)